158 related articles for article (PubMed ID: 24903080)
1. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
[TBL] [Abstract][Full Text] [Related]
2. Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: is there a subpopulation that might have benefit from adjuvant chemotherapy?
Park YH; Im SA; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Breast Cancer Res Treat; 2012 May; 133(1):247-55. PubMed ID: 22270935
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
5. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
6. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
[TBL] [Abstract][Full Text] [Related]
9. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre MM; Ramkumar C; Attuluri AK; Basavaraj C; Prakash C; Buturovic L; Madhav L; Naidu N; R P; Somashekhar SP; Gupta S; Doval DC; Pegram MD
Cancer Med; 2019 Apr; 8(4):1755-1764. PubMed ID: 30848103
[TBL] [Abstract][Full Text] [Related]
11. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
12. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Delpech Y; Wu Y; Hess KR; Hsu L; Ayers M; Natowicz R; Coutant C; Rouzier R; Barranger E; Hortobagyi GN; Mauro D; Pusztai L
Breast Cancer Res Treat; 2012 Sep; 135(2):619-27. PubMed ID: 22890751
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
Ishitobi M; Okumura Y; Arima N; Yoshida A; Nakatsukasa K; Iwase T; Shien T; Masuda N; Tanaka S; Tanabe M; Tanaka T; Komoike Y; Taguchi T; Nishimura R; Inaji H
Ann Surg Oncol; 2013 Jun; 20(6):1886-92. PubMed ID: 23292516
[TBL] [Abstract][Full Text] [Related]
15. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Bartlett JM; Christiansen J; Gustavson M; Rimm DL; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Putter H; Markopoulos CJ; Dirix LY; Seynaeve C; Rea DW
Arch Pathol Lab Med; 2016 Jan; 140(1):66-74. PubMed ID: 26717057
[TBL] [Abstract][Full Text] [Related]
16. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
17. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
20. A validated web-based nomogram for predicting positive surgical margins following breast-conserving surgery as a preoperative tool for clinical decision-making.
Pleijhuis RG; Kwast AB; Jansen L; de Vries J; Lanting R; Bart J; Wiggers T; van Dam GM; Siesling S
Breast; 2013 Oct; 22(5):773-9. PubMed ID: 23462681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
